Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
Adolescent
Algorithms
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Benchmarking
Benzimidazoles
/ administration & dosage
Brain Stem Neoplasms
/ diagnostic imaging
Chemoradiotherapy
/ methods
Child
Diffuse Intrinsic Pontine Glioma
/ diagnostic imaging
Disease Progression
Female
Humans
Image Interpretation, Computer-Assisted
/ methods
Magnetic Resonance Imaging
/ methods
Male
Neuroimaging
/ methods
Perfusion Imaging
/ methods
Prognosis
Retrospective Studies
Survival Analysis
Temozolomide
/ administration & dosage
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
21
11
2019
accepted:
10
02
2020
pubmed:
4
4
2020
medline:
27
10
2020
entrez:
4
4
2020
Statut:
ppublish
Résumé
Diffuse intrinsic pontine glioma is a lethal childhood brain cancer with dismal prognosis and MR imaging is the primary methodology used for diagnosis and monitoring. Our aim was to determine whether advanced diffusion, perfusion, and permeability MR imaging metrics predict survival and pseudoprogression in children with newly diagnosed diffuse intrinsic pontine glioma. A clinical trial using the poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor veliparib concurrently with radiation therapy, followed by maintenance therapy with veliparib + temozolomide, in children with diffuse intrinsic pontine glioma was conducted by the Pediatric Brain Tumor Consortium. Standard MR imaging, DWI, dynamic contrast-enhanced perfusion, and DSC perfusion were performed at baseline and approximately every 2 months throughout treatment. ADC histogram metrics of T2-weighted FLAIR and enhancing tumor volume, dynamic contrast-enhanced permeability metrics for enhancing tumors, and tumor relative CBV from DSC perfusion MR imaging were calculated. Baseline values, post-radiation therapy changes, and longitudinal trends for all metrics were evaluated for associations with survival and pseudoprogression. Fifty children were evaluable for survival analyses. Higher baseline relative CBV was associated with shorter progression-free survival (
Sections du résumé
BACKGROUND AND PURPOSE
Diffuse intrinsic pontine glioma is a lethal childhood brain cancer with dismal prognosis and MR imaging is the primary methodology used for diagnosis and monitoring. Our aim was to determine whether advanced diffusion, perfusion, and permeability MR imaging metrics predict survival and pseudoprogression in children with newly diagnosed diffuse intrinsic pontine glioma.
MATERIALS AND METHODS
A clinical trial using the poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor veliparib concurrently with radiation therapy, followed by maintenance therapy with veliparib + temozolomide, in children with diffuse intrinsic pontine glioma was conducted by the Pediatric Brain Tumor Consortium. Standard MR imaging, DWI, dynamic contrast-enhanced perfusion, and DSC perfusion were performed at baseline and approximately every 2 months throughout treatment. ADC histogram metrics of T2-weighted FLAIR and enhancing tumor volume, dynamic contrast-enhanced permeability metrics for enhancing tumors, and tumor relative CBV from DSC perfusion MR imaging were calculated. Baseline values, post-radiation therapy changes, and longitudinal trends for all metrics were evaluated for associations with survival and pseudoprogression.
RESULTS
Fifty children were evaluable for survival analyses. Higher baseline relative CBV was associated with shorter progression-free survival (
Identifiants
pubmed: 32241771
pii: ajnr.A6499
doi: 10.3174/ajnr.A6499
pmc: PMC7144652
doi:
Substances chimiques
Benzimidazoles
0
veliparib
01O4K0631N
Temozolomide
YF1K15M17Y
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
718-724Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA081457
Pays : United States
Informations de copyright
© 2020 by American Journal of Neuroradiology.
Références
Contrast Media Mol Imaging. 2018 Dec 2;2018:6828396
pubmed: 30627060
Neuroradiology. 2014 May;56(5):405-12
pubmed: 24626721
Neuro Oncol. 2011 Aug;13(8):904-9
pubmed: 21757444
J Neurooncol. 2015 Oct;125(1):183-90
pubmed: 26275367
Lancet Oncol. 2006 Mar;7(3):241-8
pubmed: 16510333
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Medicine (Baltimore). 2017 Mar;96(11):e6333
pubmed: 28296759
AJNR Am J Neuroradiol. 2015 Nov;36(11):2170-6
pubmed: 26338910
Acta Neuropathol. 2015 Dec;130(6):815-27
pubmed: 26399631
J Neurooncol. 2019 May;143(1):79-86
pubmed: 30810873
J Neurooncol. 2014 Mar;117(1):175-82
pubmed: 24522717
Bioinformatics. 2008 Jun 15;24(12):1461-2
pubmed: 18441000
Neuroradiology. 2016 Oct;58(10):1027-1034
pubmed: 27438806
AJNR Am J Neuroradiol. 2017 Jan;38(1):170-175
pubmed: 27633807
J Neurooncol. 2008 Feb;86(3):313-9
pubmed: 17909941
Neuro Oncol. 2018 Jun 18;20(7):994-1002
pubmed: 29244086
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):476-485
pubmed: 28871999
J Neurooncol. 2012 Jan;106(2):399-407
pubmed: 21858607
Neoplasia. 2016 Feb;18(2):82-9
pubmed: 26936394
Pediatr Blood Cancer. 2018 Feb;65(2):
pubmed: 29090526
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Adv Radiat Oncol. 2019 Mar 30;4(3):520-531
pubmed: 31360809
Neuro Oncol. 2015 Jan;17(1):160-6
pubmed: 24903904
J Nucl Med. 2017 Aug;58(8):1264-1269
pubmed: 28360212
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Neuro Oncol. 2011 Apr;13(4):417-27
pubmed: 21297126
J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101
pubmed: 9039598
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
J Neurooncol. 2016 Aug;129(1):109-21
pubmed: 27180091
Korean J Radiol. 2013 Jul-Aug;14(4):662-72
pubmed: 23901325
Pediatr Hematol Oncol. 2019 Mar;36(2):103-112
pubmed: 30978130
AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
pubmed: 16611779
Magn Reson Imaging. 1987;5(3):201-8
pubmed: 3626789
Neuro Oncol. 2016 May;18(5):725-34
pubmed: 26487690
AJNR Am J Neuroradiol. 2013 Jul;34(7):1450-5
pubmed: 23436052
AJNR Am J Neuroradiol. 2011 Feb;32(2):315-22
pubmed: 21087935
PLoS One. 2018 Aug 28;13(8):e0202860
pubmed: 30153289